Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan B Sandler

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trialsDavid M Dilts, Alan B Sandler
Seminars in Oncology|June 5, 2004
COX-2 inhibition and lung cancerAlan B Sandler, Steven M Dubinett
Cancer Science|September 26, 2007
Inhibition of angiogenesis in the treatment of non-small cell lung cancerVicki L Keedy, Alan B Sandler
Expert Opinion on Drug Safety|March 1, 2006
The safety of bevacizumabRachel E Sanborn, Alan B Sandler
Oncology (Williston Park, N.Y.)|January 24, 2006
First-line treatment for advanced non-small-cell lung cancerJanessa J Laskin, Alan B Sandler
The Oncologist|June 5, 2004
Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?Roy S Herbst, Alan B Sandler
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
The role of prophylactic cranial radiation in the treatment of non-small-cell lung cancerJanessa J Laskin, Alan B Sandler
Cancer Investigation|October 1, 2005
State of the art in therapy for non-small cell lung cancerJanessa J Laskin, Alan B Sandler
Current Oncology Reports|May 16, 2013
EGFR tyrosine kinase inhibitors: difference in efficacy and resistanceKyle W Robinson, Alan B Sandler
Clinical Lung Cancer|January 11, 2005
Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancerRoy S Herbst, Alan B Sandler
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trialsDavid M Dilts, Alan B Sandler
Seminars in Oncology|June 5, 2004
COX-2 inhibition and lung cancerAlan B Sandler, Steven M Dubinett
Cancer Science|September 26, 2007
Inhibition of angiogenesis in the treatment of non-small cell lung cancerVicki L Keedy, Alan B Sandler
Expert Opinion on Drug Safety|March 1, 2006
The safety of bevacizumabRachel E Sanborn, Alan B Sandler
Oncology (Williston Park, N.Y.)|January 24, 2006
First-line treatment for advanced non-small-cell lung cancerJanessa J Laskin, Alan B Sandler
The Oncologist|June 5, 2004
Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?Roy S Herbst, Alan B Sandler
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
The role of prophylactic cranial radiation in the treatment of non-small-cell lung cancerJanessa J Laskin, Alan B Sandler
Cancer Investigation|October 1, 2005
State of the art in therapy for non-small cell lung cancerJanessa J Laskin, Alan B Sandler
Current Oncology Reports|May 16, 2013
EGFR tyrosine kinase inhibitors: difference in efficacy and resistanceKyle W Robinson, Alan B Sandler
Clinical Lung Cancer|January 11, 2005
Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancerRoy S Herbst, Alan B Sandler
Pageof 7